Pimavanserin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Oct 26, 2016 → Jun 25, 2019
NCT ID
NCT02970292About Pimavanserin + Placebo
Pimavanserin + Placebo is a phase 3 stage product being developed by Acadia Pharmaceuticals for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02970292. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05523895 | Phase 2/3 | Completed |
| NCT04531982 | Phase 3 | Completed |
| NCT03968159 | Phase 3 | Completed |
| NCT03575052 | Phase 3 | Completed |
| NCT02970305 | Phase 2 | Completed |
| NCT02970292 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia